TKTerhi Kurko

Terhi Kurko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terhi Kurko has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5‐Year Follow‐Up

    by Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Tero Taiminen, Reijo Sund, Terhi Kurko, Jarmo Hietala, Solja Niemelä

    Introduction: We aimed to investigate the risks of all‐cause and cause‐specific mortality associated with dose‐dependent benzodiazepine and Z‐drug ( BZDR) use in the Finnish population initiating new BZDR use with five‐year follow‐up. Methods: Study subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the preceding years 2004–2005. The information drug dispensing was modeled with PRE2DUP method as time‐varying measure updated at every dispensing and then divided into three dose categories which were low dose (< 1.0 Defined Daily Doses [DDDs] per day), medium to high dose (1.0–< 3.0 DDDs/day) and very high‐dose (≥ 3.0 DDDs/day). Risk of mortality was studied with Cox regression models. Results: The study included 48,124 incident BZDR users aged 18–65 years (44.4% male). During the 5‐year follow‐up, 2294 (4.9%) individuals died. Compared to non‐use periods, BZDRs use was associated with increased mortality risk (adjusted Hazard Ratio HR 1.28, 95% Confidence Interval CI 1.16–1.41). Compared to the time periods when BZDRs were not used, both medium to high‐dose use ( aHR 1.58, 1.36–1.74) and very‐high‐dose use ( aHR 2.68, 95% CI 2.20–3.26) were associated with an increased risk of all‐cause mortality, whereas low dose use was not. The highest risk estimates were observed during very high‐dose use and for potentially preventable deaths such as overdoses ( aHR 6.18, 95% CI 3.77–10.12), suicides ( aHR 4.46, 95% CI 2.79–7.13), and accidents ( aHR 3.77, 95% CI 2.66–5.35). Conclusions: Persons using BZDRs in very high doses are at a six‐fold increased risk of overdose deaths compared to non‐use, and those using BZDRs in medium to high doses are at a three‐fold increased risk. In low doses, however, the risk of all‐cause mortality was not elevated. The mortality risk strongly associates with higher doses and is often characterized by concomitant use of more than one BZDRs at the same time.

  • Open Access

    Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

    by Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko

    Purpose: Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis. Subsequently, the European Medicines Agency (EMA) issued multiple safety alerts concerning this drug class. We aimed to examine how the use of JAKis developed in Finland. Methods: We conducted a retrospective time series analysis on the initiations and use of JAKis in the treatment of IRMD and IBD, utilising the national medicines reimbursement registry 2018–2023, including nearly all JAKi prescriptions. We assessed the initiators' age, line of treatment and atherosclerotic risk factors. Results: Between 2018 and 2023, the prevalence of JAKi use increased from 0.14 to 0.43/1000 inhabitants, from 756 to 1740 among IRMD patients and from 11 to 672 among IBD patients. In IRMD , JAKis were rapidly adopted with 677 initiations in 2018, declining to 328 initiations in 2023. The corresponding numbers in IBD were 11 in 2018 and 358 in 2023. The mean age of IRMD patients initiating JAKis decreased from 54 years in 2021 to 41 years in 2023, while IBD patients' mean age changed from 42 to 39 years. In 2020, 52% of IRMD Patients Initiated JAKi in second‐line of treatment but by 2023, this decreased to 31%. Prevalence of atherosclerotic risk factors declined. Conclusions: The uptake of JAKis among IRMD patients were initially fast. After safety alerts, initiation rates declined and shifted towards younger patients with fewer atherosclerotic risk factors. In contrast, the uptake of JAKis among IBD patients increased steadily.

  • Open Access

    EMA approved orphan medicines since the implementation of the orphan legislation

    by Eveliina Hahl, Terhi Kurko, Hanna Koskinen, Marja Airaksinen, Kati Sarnola

    Background: In the European Union (EU), the orphan legislation, aiming to increase the number of pharmacotherapies available for rare diseases, came into force in April 2000. This study examined the development of the selection of orphan medicines granted marketing authorisation, their approved indications, and the number of orphan medicines developed for paediatric use in EU during 2000–2022. This study also examined the availability of the orphan medicines with a marketing authorisation in the Finnish market in order to demonstrate their country level uptake in a single member state. Methods: The material on orphan medicines’ marketing authorisations and their introduction were collected from the European Commission’s Community Registers in June 2022 and analysed with a qualitative document analysis. This study covered the period 2000–2022 since the introduction of the orphan legislation, and comparisons were made in 10-year periods of, 2001–2010 and 2011–2020. Results: By May 2022, there were 213 novel orphan medicines approved in Europe during the observation period. Of them, 67% (n = 142) were on the market in Finland in May 2024. The number of new orphan medicines approved in Europe doubled from 63 products in 2001–2010 to 127 products in 2011–2020. Several orphan medicines were developed for certain type of rare diseases, such as haematological cancers. The proportion of orphan medicines approved for paediatric use decreased from 55% in 2001–2010 to 42% in 2011–2020. Conclusion: The number of orphan medicines available within EU increased significantly after the orphan legislation came into force. The development of orphan medicines seemed to often focus on diseases or disease groups that already have available treatment options, while several rare diseases remain without available treatment. Even though rare diseases are more common in children, orphan medicines have not been developed for paediatric use in the same proportion.


  • Open Access

    New cancer medicines in Europe 2010–2020: comparison of medicines with or without extensions of indications

    by Anna-Maria Ruuskanen, Terhi Kurko, Kati Sarnola, Katariina Klintrup, Hanna Koskinen

    Introduction During the last decade, extensions of therapeutic indications have been one of the most common methods to extend the lifecycle of a medical product in the post-authorisation phase and to increase the use and sales of medicines. The aim of this study was to gain understanding of the lifecycle of cancer medicines and especially the role and level of evidence extensions in comparison to first indications. Materials and methods We identified all new outpatient cancer medicines approved by the European Medicines Agency between 2010 and 2020 and the extensions to their indications. We compared general study design characteristics from the European public assessment reports using critical appraisal tools and clinical added value assessments. Results We identified altogether 55 new outpatient cancer medicines, 31 of which had one or more extension(s) of indication and 24 had no extension of indication. In total, there were 57 extensions. The most common extension of indication was a change in the treatment line (35%). Compared with first indications, the overall quality of studies supporting extensions was better in terms of study designs. The proportion of medicines providing CAV was higher in extensions compared with first indication of medicines with and without extensions. Conclusions Based on different assessments and perspectives, we found that extensions of indications are a very common and important part of extending the lifecycle of outpatient cancer medicines in Europe. Our findings also suggest that the clinical value of cancer medicines increases with extensions.


  • Open Access

    Sleep medicines are often prescribed for older adults (≥75 years) without appropriate dosing instructions: A nationwide retrospective register study in Finland

    by Sini‐Tuulia Eronen, Terhi Kurko, Sirkka‐Liisa Kivelä, Tiina Paunio, Marja Airaksinen, Tomi Rantamäki

    Background: Sleep medicines should be prescribed cautiously, accompanied by instructions that ensure appropriate use and reduce risks. This is especially important for older adults, for whom many of these medicines are classified as potentially inappropriate medicines.Methods: We investigated the use and appropriateness of dosing instructions for sleep medicines (described in the Finnish National Current Care Guideline for Insomnia) prescribed for older adults (≥75 years) and dispensed with instruction label in pharmacies. The retrospective reimbursement register data for year 2020 by the Social Insurance Institution of Finland was used as the data source (1,080,843 purchases by 143,886 individuals of which 565,228 purchases were pharmacy dispenses). The appropriateness of the pharmacy dosing instructions containing keyword(s) referring to insomnia treatment was examined according to the prescribed dose, time of intake, frequency of use, and warnings/remarks. A random sample of 1000 instructions was used to manually analyze the phrasing and appropriateness.Outcomes: We focused our analysis on 58.1% (328,285 purchases by 87,396 individuals) of the pharmacy dispenses, which contained dosing instructions referring insomnia treatment. Of these, zopiclone and mirtazapine were the most prescribed drugs (134,631 and 112,463 purchases, respectively). Dose and time of intake were specified in most of the instructions (98.4% and 83.4%, respectively), whereas frequency of use was specified in 57.3%. A small percentage of the instructions included warnings/remarks (2.8%). Overall, only 2.1% of the instructions contained information about a single dose, time of intake, temporary use, and warnings/remarks and were thus defined as sufficient. Notably, 47.7% (n = 515,615) of all the purchases in our dataset were dispensed via automated multi‐dose dispensing systems, which is aimed for long‐term treatment.Interpretation: It is common to prescribe sleep medicines for older adults without appropriate dosing instructions, particularly excluding warnings against long‐term, regular use. Actions to change the current prescribing practices are warranted.


  • Open Access

    The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis

    by Hanna Rättö, Terhi Kurko, Jaana E. Martikainen, Katri Aaltonen


  • Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014

    by Terhi Kurko, Leena K. Saastamoinen, Annamari Tuulio‐Henriksson, Tero Taiminen, Jari Tiihonen, Marja Airaksinen, Jarmo Hietala

    Purpose: Long‐term benzodiazepine (BZD) treatment continues to be a debated topic. Because individual BZDs have different clinical profiles, we assessed the nationwide trends of long‐term BZD use at active substance level during years 2006 to 2014.Methods: This study covered all reimbursed BZD purchases (n = 408 572‐521 823 annually) for adults recorded in the Finnish Prescription Register. We assessed long‐term use (annual cumulative purchase of ≥180 defined daily doses) in general, and at active substance level with the most commonly used BZD anxiolytics (oxazepam, diazepam, alprazolam, and clonazepam for nonepilepsy indications) and hypnotics (zopiclone, zolpidem, and temazepam) included. The persistence rates for each substance were assessed separately.Results: The prevalence of long‐term BZD use among Finnish adults declined significantly from 5.3% to 3.6%, during years 2006 to 2014. Despite this decline, there was a significant increase in the long‐term use of clonazepam for nonepilepsy indications and zolpidem (28.0% and 17.5%, respectively). Long‐term use was common in the aged population, as well as among the users of hypnotics or clonazepam. Persistent use of 9 consecutive calendar years varied between 7.5% for incident alprazolam users and 21.0% for incident clonazepam users.Conclusions: We found a declining trend in long‐term BZD use, but the decline was not uniform between the substances—the long‐term use of clonazepam and zolpidem even increased. Follow‐up research is needed to assess whether the decline in BZD use is accompanied by an increased use of other types of anxiolytic or hypnotic drugs or other forms of treatment.


  • Top Cited Papers

    Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies

    by T.A.T. Kurko, L.K. Saastamoinen, S. Tähkäpää, A. Tuulio-Henriksson, T. Taiminen, J. Tiihonen, M.S. Airaksinen, J. Hietala

    Background: Numerous treatment guidelines recommend that long-term use of benzodiazepines (BZD) should be avoided primarily due to development of tolerance and a risk for BZD dependence. Despite this, long-term BZD use remains a controversial subject in clinical patient care with “for and against” debates. However, there is no explicit understanding of what is meant by long-term BZD use in real world. The aim of this study was to assess different definitions, usage patterns, prevalence and other characteristics of long-term BZD use based on published register-based studies. Synthesis of these characteristics is essential to derive a meaningful definition of long-term BZD.Methods: Systematic review of register-based studies on long-term BZD use published in 1994–2014.Results: Fourty-one studies met our predetermined inclusion criteria. The length of BZD use defined as “long-term” varied in these studies ranging from one month to several years. The most common definition was six months or longer during a year. The prevalence of long-term BZD use in the general population was estimated to be about 3%. The relative proportion of long-term BZD users (all definitions) in adult BZD users ranged from 6% to 76% (mean 24%; 95% CL 13–36%). The estimates were higher in studies only on the elderly (47%; 95% CL 31–64%). Long-term use involved typically steady treatment with low BZD doses. However, in elderly patients long-term BZD use and exceeding recommended doses was relatively common. Several characteristics associated with long-term use were found.Conclusions: Long-term BZD use is common and a clinical reality. Uniform definitions for “long-term”, which is in line with population-based evidence, is needed to have more comparable results between studies. Our systematic review suggests that duration of BZD treatment over six months, the most common definition for long-term BZD use in the included studies. As also recommended previously, it is a useful starting point for further analyses on disadvantages but also potential advantages associated with long-term BZD use.


  • Is nicotine replacement therapy overvalued in smoking cessation? Analysis of smokers' and quitters' communication in social media

    by Terhi Kurko, Kari Linden, Maija Kolstela, Kirsi Pietilä, Marja Airaksinen

    Background: Internet discussion forums provide new, albeit less used data sources for exploring personal experiences of illness and treatment strategies.Objective: To gain an understanding of how discussion forum participants value nicotine replacement therapy (NRT) in smoking cessation (SC).Setting: Finnish national Internet‐based discussion forum, STUMPPI, supporting SC and consisting of ten free discussion areas, each with a different focus. The analysis was based on STUMPPI forum participants’ postings (n = 24 481) in five discussion areas during January 2007–January 2012.Design: Inductive content analysis of the postings concerning NRT use or comparing NRT to other SC methods.Results: Three major themes related to NRT in SC emerged from the discussions. These were as follows: (I) distrust and negative attitude towards NRT; (II) neutral acceptance of NRT as a useful SC method; and (III) trust on the crucial role of NRT and other SC medicines. The negative attitude was related to following perceptions: NRT use maintains tobacco dependence, fear of NRT dependence or experience of not gaining help from NRT use. NRT was perceived to be useful particularly in the initiation of SC attempts and in dealing with physiological dependence. The most highlighted factors of successful quitting were quitters’ own psychological empowerment and peer support from the discussion community.Conclusions: The majority of STUMPPI forum participants had low or balanced expectations towards the role of NRT in SC. More research from the smokers’ and quitters’ perspective is needed to assess the real value of NRT compared to other methods in SC.